>
Conmed logo

CNMD - Conmed Share Price

$136.99 0.7  0.5%

Last Trade - 11/06/21

Sector
Healthcare
Size
Large Cap
Market Cap £2.83bn
Enterprise Value £3.33bn
Revenue £624.6m
Position in Universe 1661st / 6911
Bullish
Bearish
Unlock CNMD Revenue
Momentum
Relative Strength (%)
1m -3.03%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -6.78%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
719.2 763.5 796.4 859.6 955.1 862.5 1,020 1,100 +3.7%
-11.2 -15.4 +8.1 +5.8 +0.6 -62.0 +406.2 +18.1
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2021, ConmedCorp revenues increased 9% to $232.7M. Net income increased66% to $9.9M. Revenues reflect Asia Pacific segmentincrease of 36% to $39.3M, United States segment increaseof 4% to $123.9M. Net income benefited from Manufacturingconsolidation costs decrease from $1.8M (expense) to $0K,Business acquisition costs decrease from $805K (expense) to$0K. Dividend per share remained flat at $0.20.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CNMD Revenue Unlock CNMD Revenue

Net Income

CNMD Net Income Unlock CNMD Revenue

Normalised EPS

CNMD Normalised EPS Unlock CNMD Revenue

PE Ratio Range

CNMD PE Ratio Range Unlock CNMD Revenue

Dividend Yield Range

CNMD Dividend Yield Range Unlock CNMD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CNMD EPS Forecasts Unlock CNMD Revenue
Profile Summary

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. The Company's product lines consist of orthopedic surgery and general surgery.

Directors
Last Annual December 31st, 2020
Last Interim March 31st, 2021
No. of Shareholders: 518
No. of Employees: 3,400
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange New York Stock Exchange
Shares in Issue 29,092,141
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CNMD Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CNMD
Upcoming Events for CNMD
Monday 14th June, 2021
Dividend For CNMD.N - 0.2000 USD
Tuesday 27th July, 2021 Estimate
Q2 2021 Conmed Corp Earnings Release
Tuesday 26th October, 2021 Estimate
Q3 2021 Conmed Corp Earnings Release
Frequently Asked Questions for Conmed
What is the Conmed share price?

As of 11/06/21, shares in Conmed are trading at $136.99, giving the company a market capitalisation of £2.83bn. This share price information is delayed by 15 minutes.

How has the Conmed share price performed this year?

Shares in Conmed are currently trading at $136.99 and the price has moved by 93.57% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Conmed price has moved by 38.87% over the past year.

What are the analyst and broker recommendations for Conmed?

Of the analysts with advisory recommendations for Conmed, there are there are currently 1 "buy" , 3 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Conmed is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Conmed next release its financial results?

Conmed is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Conmed dividend yield?

The Conmed dividend yield is 0.58% based on the trailing twelve month period.

Does Conmed pay a dividend?

Last year, Conmed paid a total dividend of 0.8, and it currently has a trailing dividend yield of 0.58%. Looking ahead, shares in Conmed are due to go ex-dividend on 2021-06-14 and the next dividend pay date is 2021-07-06.

When does Conmed next pay dividends?

Conmed are due to go ex-dividend on 2021-06-14 and the next dividend pay date is 2021-07-06. The historic dividend yield on Conmed shares is currently 0.58%.

How do I buy Conmed shares?

To buy shares in Conmed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Conmed?

Shares in Conmed are currently trading at $136.99, giving the company a market capitalisation of £2.83bn.

Where are Conmed shares listed? Where are Conmed shares listed?

Here are the trading details for Conmed:

Country of listing: United States
Exchange: NYQ
Ticker Symbol: CNMD
What kind of share is Conmed?

Based on an overall assessment of its quality, value and momentum, Conmed is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Conmed share price forecast 2021?

Shares in Conmed are currently priced at $136.99. At that level they are trading at 15.15% discount to the analyst consensus target price of 0.00.

Analysts covering Conmed currently have a consensus Earnings Per Share (EPS) forecast of 3.151 for the next financial year.

How can I tell whether the Conmed share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Conmed. Over the past six months, the relative strength of its shares against the market has been 13.81%. At the current price of $136.99, shares in Conmed are trading at 22.92% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Conmed PE Ratio?

The Conmed PE ratio based on its reported earnings over the past 12 months is 0.227k. The shares are currently trading at $136.99.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Conmed?

Conmed's management team is headed by:

Daniel Jonas - EVP
Mark Tryniski - DRC
Brian Concannon - IND
Terence Berge - VPR
Patrick Beyer - CEX
John Kennedy - VPR
Stanley Peters - VPR
David Bronson - IND
Martha Aronson - LED
Laverne Council - IND
Who are the major shareholders of Conmed?

Here are the top five shareholders of Conmed based on the size of their shareholding:

BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 14.93% (4.34m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 10.71% (3.12m shares)
iShares Core S&P Small-Cap ETF Mutual Fund
Percentage owned: 6.68% (1.94m shares)
Champlain Investment Partners, LLC Investment Advisor
Percentage owned: 5.86% (1.70m shares)
EARNEST Partners, LLC Investment Advisor/Hedge Fund
Percentage owned: 5.63% (1.64m shares)
Similar to CNMD
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.